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Dear editor,  
Pregnancy success rates in women with systemic lupus erythematosus (SLE) have improved 
significantly in recent years, in that pregnancy morbidity has been reduced from 40% in the 
early 1960’s to less than 15% in recent years [1]. Pregnancy was previously discouraged in 
women with SLE, but the twenty-first century has brought focus on pregnancy management 
and in maternal and fetal outcomes and recent data suggest that women with stable SLE (if 
adequately treated) have favourable pregnancy outcomes with live birth rates as high as 80% 
[2]. In a systematic review on observational studies,  Smyth et al found that in patients with 
SLE, both lupus nephritis (LN) and antiphospholipid antibodies (aPL) increase the risks for 
maternal hypertension and premature births[3].  
We would like to congratulate Moroni and her team for publishing the first prospective 
multicentre data on maternal and fetal pregnancy outcomes in women with a history of LN [4, 
5]. These data are urgently needed and provide a further piece in the puzzle towards a more 
complete picture in the understanding of pregnancy outcomes in women with SLE and in 
particular in patients with underlying LN. The only previous prospective data on women with 
LN focused on SLE activity after switching mycofenolate mofetil maintenance to azathioprine 
prior to conception [6].   
Moroni et al included 61 women (59 Caucasians and 2 Asians) assessing 71 pregnancies 
followed from 2006-2013, who fulfilled the American College of Rheumatology (ACR) 
classification criteria for SLE, with a biopsy or clinically diagnosed LN and who fell pregnant 
in the above mentioned period attending the pregnancy clinic 3 months prior to conception. 
Women were closely followed up on a monthly basis.  
 
Assessing maternal outcomes, 19.7% of the patients flared (18.3% were reported as mild and 
1.7% as severe), 8.4% developed pre-eclampsia and two cases developed haemolysis and 
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elevated liver enzymes and low platelet count (HELLP syndrome). Predictors of maternal 
outcomes were SLE duration, previous renal flares and arterial hypertension, whereas 
significant predictors of flares were BMI, hypo-complementaemia (low C3 and C4), anti-
double-stranded DNA antibodies and anti-C1q antibodies [4].  
 
With regards to fetal outcomes, the reported live birth rate was 91.8%, and the 8.2% fetal loss 
rate was divided into 4.1% miscarriages (in this study defined as pregnancy loss < 20 weeks 
of gestation) and 4.1% stillbirths. Of the live-births, 61% were delivered at term, 30% were 
born pre-term and 27% had a birth weight < 2500g. All patients received aspirin. Factors 
associated with fetal loss were lupus anticoagulant, anti-cardiolpipin IgG, anti-glycoprotein-I 
and pre-existing arterial hypertension. SLE activity, proteinuria, a history of renal flares, 
arterial hypertension and active LN increases the risk of preterm delivery [5].  
There are three aspects of particular note with regards to fetal outcomes which supplement 
previous data very nicely; Firstly, that an increase in SLEDAI and proteinuria seem to increase 
the likelihood for preterm delivery. Albeit based on a relatively low event rate, this 
information was not available from previous data and might guide clinicians in their decision 
making in the management of these patients.  Secondly, a reassuringly low rate of fetal loss 
was observed (in this study defined as neonatal death within 28 days post delivery). It may 
well be that this has been influenced by the fact that all women were treated with aspirin. 
Thirdly, an interesting observation was that women who were taking hydroxychloroquine 
(HCQ) had a significantly reduced risk to deliver a small for gestational aged baby (p=0.023). 
In their cohort Moroni et al reported that 54.4% of women were treated with HCQ. It would 
be most interesting to know if these women treated with HCQ had more favourable classes of 
LN, if they generally had more stable disease profiles, if HCQ was given as adjuvant therapy in 
addition to other immunosuppressive or anticoagulation therapy and most importantly if 
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these women were more likely to have persistent aPL?  
 
HCQ is currently experiencing its ‘renaissance’ in the field of antiphospholipid syndrome 
(APS) [7] and has recently been shown to improve pregnancy outcomes in women with aPL 
and APS [8, 9]. Its favourable safety profile especially in regards to pregnancy and lactation 
makes it an interesting agent for the use in pregnancy. Latest the British Society for 
Rheumatology (BSR) has recommended HCQ as ‘the antimalarial of choice in women requiring 
immune modulation in pregnancy’ [10, 11]. It would be interesting to know if HCQ in the future 
also will have a more substantial post in the armamentarium available for LN and  prospective 
studies defining HCQ’s role in autoimmune diseases are therefore urgently needed[7, 12]. 
It is worth remembering that patients included in this study were mainly Caucasian, and it 
may therefore be difficult to draw conclusions for all pregnant LN patients. Moreover, the 
team report that 21.1% of the patients had pre pregnancy LN activity (full remission was only 
present in 78.9%), which seems rather high given the fact that in general full disease 
remission is recommended for at least 6 months prior to conception [13]. Thus, pregnancy 
outcomes may have been even more encouraging if these cases were excluded from analysis. 
However, at the end of the day every clinician has experienced that real patients are not 
always compliant with textbook recommendations, and these data therefore provide valuable 
information how to gauge patients in full remission and those with mild LN activity prior to 
embarking pregnancy. Once more this study highlights the importance of specialist 
multidisciplinary teams and pregnancy counselling in women with pre-existing medical 
illnesses [14][15].  
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